Fibrocell Announces Proposed Public Offering of Common Stock and Warrants
August 08 2016 - 4:30PM
Fibrocell Science, Inc. (NASDAQ:FCSC) (Fibrocell) today announced
that it intends to offer and sell shares of its common stock and
related warrants to purchase shares of its common stock in an
underwritten public offering. The shares of common stock and
related warrants will be immediately separable and will be issued
separately. All of the securities in the offering are to be sold by
Fibrocell.
Fibrocell intends to use the net proceeds of the
proposed offering for the continued clinical and pre-clinical
development of its product candidates and for other general
corporate purposes.
Cantor Fitzgerald & Co. is acting as sole
book-running manager for the offering. Roth Capital Partners, LLC
and Griffin Securities, Inc. are acting as co-managers for the
offering. Fibrocell intends to grant the underwriters a
30-day option to purchase up to an additional 15 percent of the
shares of common stock and warrants sold in the public offering to
cover over-allotments, if any. The offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or
terms of the offering.
The offering is being made by Fibrocell pursuant
to a shelf registration statement on Form S-3 previously filed with
the U.S. Securities and Exchange Commission (the SEC), which the
SEC declared effective on February 9, 2016. The offering will be
made only by means of the written prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement related to the offering will be
filed with the SEC and will be available on the website of the SEC
at www.sec.gov. Copies of the preliminary prospectus
supplement may also be obtained from Cantor Fitzgerald & Co.,
499 Park Avenue, New York, NY 10022; Attention: Equity Capital
Markets; Phone: (212) 915-1210; Email:
Eric.Sivin@cantor.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
state or jurisdiction.
About Fibrocell
Fibrocell is an autologous cell and gene therapy
company translating personalized biologics into medical
breakthroughs for diseases affecting the skin and connective
tissue. Fibrocell’s most advanced gene-therapy product
candidate, FCX-007, has begun a Phase I/II trial for the treatment
of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is
in pre-clinical development of FCX-013, its gene-therapy product
candidate for the treatment of linear scleroderma. In
addition, Fibrocell has a third gene-therapy program in the
research phase for the treatment of arthritis and related
conditions. Fibrocell’s gene-therapy portfolio is being
developed in collaboration with Intrexon Corporation (NYSE: XON), a
leader in synthetic biology. For more information, visit
www.fibrocell.com or follow us on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo, and Fibrocell
Science are trademarks of Fibrocell Science, Inc. and/or its
affiliates. All other names may be trademarks of their
respective owners.
Forward-Looking Statements
This press release contains, and Fibrocell’s
officers and representatives may from time to time make, statements
that are “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements relate
to a variety of matters, including, without limitation, Fibrocell’s
expectations regarding the sale of shares of its common stock in
the proposed public offering, its use of the proceeds from the
proposed offering and other statements that are not purely
statements of historical fact.
Any forward-looking statement made by Fibrocell
in this press release is based only on information currently
available to Fibrocell and speaks only as of the date on which it
is made. In addition, Fibrocell operates in a highly competitive
and rapidly changing environment, and new risks may arise.
Accordingly, you should not place any reliance on forward-looking
statements as a prediction of actual results. Fibrocell disclaims
any intention to, and undertakes no obligation to, update or revise
any forward-looking statement. You are also urged to carefully
review and consider the various disclosures in Fibrocell’s most
recent Form 10-K and Form 10-Q filings as well as Fibrocell’s other
public filings with the SEC since the filing of its most recent
Form 10-K.
Investor Relations Contact:
John Woolford
Westwicke Partners
443.213.0506
john.woolford@westwicke.com
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jul 2023 to Jul 2024